Le Lézard
Classified in: Health
Subjects: TRI, PLW

New AstaReal Patent Leads the Way for Natural Astaxanthin in Personalized Nutrition


BURLINGTON, N. J., April 16, 2021 /PRNewswire/ -- AstaReal, pioneer and global leader in the production of natural Astaxanthin, has always strived for excellence and advancement of natural astaxanthin research and product development. AstaReal's new patent is directly relevant to personalized nutrition applications of natural astaxanthin in supplements, functional foods, and functional beverages.

Precision nutrition products are tailored to an individual's characteristic needs and goals, and are aimed at promoting long-term health. AstaReal USA Inc. CEO, Arun Nair commented, "This is an exciting new path for AstaReal® Astaxanthin, addressing the growing contribution of nutrigenomics to the supplement and functional foods market."

Nutrients and bioactive molecules in foods can influence our health in many ways; by directly interacting with metabolic pathways, by fueling growth, and by modulating gene expression. AstaReal's new patent paves the way for AstaReal® Astaxanthin application in personalized nutrition products aimed at maintaining mobility and healthy muscles. This preventative healthcare approach is relevant to individuals concerned with aging muscles (i.e. sarcopenia), muscles prone to injury (i.e. athletes), and unloaded muscles (i.e. astronauts). The patent highlights research in which AstaReal® Astaxanthin was able to lower rates of muscle atrophy in response to muscle denervation and nerve injury. AstaReal® Astaxanthin shifted gene expression profiles to favor the maintenance of healthy muscle mass.

AstaReal USA Inc. Scientific Affairs Manager, Dr. Karen Hecht added, "The demand for customized nutrition is on the rise, and this AstaReal® Astaxanthin patent represents an opportunity to engage in the growing consumer awareness of science-based supplements and their role in tailored nutritional solutions." 

For more information on AstaReal USA, visit www.astarealusa.com.

SOURCE AstaReal Inc., USA


These press releases may also interest you

at 07:35
Neurogene Inc. , a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced first quarter 2024 financial results and highlighted recent corporate updates....

at 07:35
The judgment in Bennett, et. al v. Providence Health & Services, was entered in King County Superior Court yesterday, the culmination of a two-week trial which took place late last month. Providence is ordered to pay more than 33,000 of its hourly...

at 07:30
Soligenix, Inc. (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and...

at 07:05
Dentalcorp Holdings Ltd. ("Dentalcorp" or the "Company") , Canada's largest and one of North America's fastest growing networks of dental practices, today announced its financial and operating results for the first quarter ended March 31, 2024. All...

at 07:05
Castle Biosciences, Inc. , a company improving health through innovative tests that guide patient care, today announced that it has been selected as the winner of the "Best Overall Mental Health Solution" award in the eighth annual MedTech...

at 07:05
REGENXBIO Inc. today announced it will participate in the following upcoming investor conferences: BofA Securities Health Care Conference 2024Fireside Chat: Wednesday, May 15, 2024 at 2:20 p.m. ETLocation: Las Vegas, NV Stifel 2024 Tailoring Genes...



News published on and distributed by: